Therapeutic effects of garenoxacin in murine experimental secondary pneumonia by Streptococcus pneumoniae after influenza virus infection

  • Diagn Microbiol Infect Dis. 2014 Feb;78(2):168-71. doi: 10.1016/j.diagmicrobio.2013.11.003.
Yoshiko Fukuda  1 ,  Yuri Furuya  2 ,  Yusuke Nozaki  2 ,  Masahiro Takahata  2 ,  Nobuhiko Nomura  2 ,  Junichi Mitsuyama  2
Affiliations
  • 1. Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan. Electronic address: [email protected].
  • 2. Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan.
PMID: 24321356 DOI: 10.1016/j.diagmicrobio.2013.11.003
Abstract

In a pneumococcal pneumonia murine model following Influenza Virus infection, garenoxacin was more effective than Other fluoroquinolones and demonstrated high levels of Bacterial eradication in the lung, low mortality, and potent histopathological improvements. Garenoxacin could potentially be used for the treatment of secondary pneumococcal pneumonia following influenza.

Keywords
Garenoxacin; In vivo efficacy; Influenza; Secondary bacterial pneumonia; Streptococcus pneumoniae.
Products